Project Grant H8E38732

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $20,435,036 Cooperative Agreement to Health Research, Inc. under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). The ELC program aims to enhance public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases. Through this award, Health Research, Inc. will provide comprehensive public health research, surveillance, prevention, and...

Numentus Technologies Inc. received a $303,685 Project Grant award from the National Science Foundation on February 15, 2021 to develop rapid planar PCR technology for COVID-19 testing. The award was made under the NSF's Engineering program (CFDA 47.041) to support innovation and excellence in engineering research. Through this funding, Numentus will work to advance the development of planar PCR, a technology that enables highly sensitive COVID-19 detection on a single integrated testing...

The Centers for Disease Control and Prevention (CDC) awarded a $194,114 Cooperative Agreement under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323) to the Indiana Department of Health. The award, which runs from August 1, 2024 to July 31, 2029, aims to strengthen the state's public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases. Key activities supported by the funding include epidemiological...

This $968,765 Project Grant awarded by the National Science Foundation's (NSF) Division of Mathematical Sciences (CFDA 47.049 - Mathematical and Physical Sciences) will develop a flexible modeling framework to simulate the impact of various testing-based infection control strategies for respiratory pathogens like SARS-CoV-2. The project aims to improve our ability to control existing respiratory diseases and enhance preparedness for future pandemics. Key deliverables include: Developing a...

This $960,000 National Science Foundation project grant supports the development of a multiplexed plasmon-enhanced lateral flow assay for point-of-care detection of SARS-CoV-2 RNA and antigens. Funded under the NSF Engineering program (CFDA 47.041), the grantee, Washington University, will design, validate and build a novel diagnostic platform with sensitivity exceeding standard laboratory tests. Key deliverables include an ultrasensitive multiplexed lateral flow assay for simultaneous...

The National Science Foundation awarded a $220,000 Project Grant to the University of Connecticut under the Engineering (47.041) federal grant program. The award will fund development of a compact, field-portable biophotonics instrument for automated analysis and identification of blood cells impacted by COVID-19. The instrument aims to provide real-time sensing and diagnosis capabilities with high accuracy, specificity and sensitivity for potential early detection of COVID-19 infections. It...

The Public Health Foundation Enterprises, Inc. (Heluna Health) was awarded a $4,212,357 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). This 5-year award, effective from August 1, 2024 to July 31, 2029, will support a range of activities to enhance California's public health infrastructure for detecting, responding to, preventing, and controlling infectious...

This federal Cooperative Agreement award, valued at $1,499,856.00 and awarded by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323), supports the University of Rochester in its efforts to promote non-mandated vaccination through "Trusted School Messengers". The project, which runs from September 30, 2024 to September 29, 2027, aims to enhance public health infrastructure for...

The Task Force for Global Health, Inc. was awarded a $2,475,519.00 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). The project period runs from August 1, 2024 to July 31, 2029. The purpose of this ELC Cooperative Agreement is to enhance the capacity of public health agencies to effectively detect, respond, prevent, and control known and emerging infectious diseases....

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $40.4 million cooperative agreement to Exela Pharma Sciences, LLC (Exela) to expand industrial base capabilities for COVID-19 response. With a period of performance from May 2022 through May 2034, this cooperative agreement will support Exela under the Research on Chemical and Biological Defense program (CFDA 12.360). Through this cooperative agreement, Exela will further the government's...